|
KMID : 0360320010330060489
|
|
Journal of Korean Cancer Research Association
2001 Volume.33 No. 6 p.489 ~ p.494
|
|
|
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregional Esophageal Cancer
|
|
이경원/Gyeong Won Lee
강정훈/김훈구/황인규/심기식/김석현/이원섭/정운태/이옥재/조중현/장정순/채규영/이종석/Joung Hun Kang/Gun Gu Kim/In Gyu Hwang/Ki Shik Shim/Seok Hyun Kim/Won Sup Lee/Woon Tae Jung/Ok Jae Lee/Jung Hyeun Cho/Joung Soon Jang/Kyu Young Chae/Jong Seok Lee
|
|
|
Abstract
|
|
|
PURPOSE:
The object of this study is to evaluate the efficacy and toxicity of induction chemotherapy followed by concomitant chemoradiotherapy in locoregional esophageal cancer.
MATERIALS AND METHODS:
Between December 1992 and December 1999, 43 patients with locoregional esophageal cancer were enrolled in this phase II trial. Patients were treated with 2-cycles of induction chemotherapy followed by concomitant chemoradiotherapy. F-P chemotherapy consists of 1,000 mg/m2/Day of 5-FU as continuous infusion on day 1~5 and 80 mg/m2 of cisplatin as an intravenous bolus on day 1 and was repeated every 3~4 weeks. All patients received 60 Gy of external beam radiation concomitantly with F-P chemotherapy; intraluminal brachytherapy was added in 12 patients. A total of 4 cycles of chemotherapy were delivered. No further treatment was planned in patients who achieved complete remission after completion of the treatment.
RESULTS:
Among the 43 patients entered, 35 patients completed the protocol. Of the 35 evaluable patients, 12 patients (34%) achieved complete response and 13 patients (37%) achieved partial response. In 26 of 33 patients, dysphagia was improved. At a median follow-up of 22 months, the 2-year and 5-year survival rates were 39% and 19%, respectively. The median survival duration of the complete responder group was 69 months (4~100 months) and the 2-year survival rate of the complete responder group was 82%. Toxicities were tolerable, comprised of mucositis and cytopenia.
CONCLUSION:
Induction chemotherapy followed by concurrent chemoradiotherapy in locoregional esophageal cancer is well tolerated and effective.
|
|
|
KEYWORD
|
|
|
Esophageal neoplasm, Induction chemotherapy, Concurrent chemoradiotherapy,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|